Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
暂无分享,去创建一个
N. Hacohen | A. Gnirke | D. Schadendorf | B. Schilling | L. Garraway | D. Neuberg | D. Keskin | R. Langer | C. Lian | E. V. Van Allen | Catherine J. Wu | F. Hodi | J. Wolchok | A. Meissner | S. Shukla | Q. Zhan | T. Merghoub | Ying Huang | E. Allen | Diana Miao | M. Babadi | J. Weber | Kendell Clement | P. Bachireddy | Christina Galonska | Arman W. Mohammad | G. Murphy | D. Gusenleitner | A. Snyder | Patrick C. Lee | C. Bango | Zachary J. Cartun | P. R. Potts | Jeffrey S. Weber | George F. Murphy | Catherine J. Wu | Levi A. Garraway | Patrick C. Lee | Patrick R. Potts
[1] Anna K. Lee,et al. A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. , 2017, Journal of molecular biology.
[2] J. Wargo,et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.
[3] Nadeem Riaz,et al. Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy , 2016, Nature Genetics.
[4] A. Enk,et al. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[6] F. Di Virgilio,et al. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. , 2016, Cancer cell.
[7] R. de Cabo,et al. Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. , 2016, Cancer cell.
[8] C. Horak,et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. , 2016, The Lancet. Oncology.
[9] Moon Soo Kim,et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.
[10] R. Langer,et al. Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas , 2016, Oncotarget.
[11] Ya-jun Guo,et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse , 2016, Science Translational Medicine.
[12] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[13] Lin Zhang,et al. The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis , 2016, Nature Communications.
[14] Anushya Muruganujan,et al. PANTHER version 10: expanded protein families and functions, and analysis tools , 2015, Nucleic Acids Res..
[15] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[16] George F. Murphy,et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.
[17] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[18] R. Langer,et al. Reliable LC3 and p62 Autophagy Marker Detection in Formalin Fixed Paraffin Embedded Human Tissue by Immunohistochemistry , 2015, European journal of histochemistry : EJH.
[19] Pornpimol Charoentong,et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.
[20] M. White,et al. Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase , 2015, Cell.
[21] I. Schmitz,et al. Autophagy in T‐cell development, activation and differentiation , 2015, Immunology and cell biology.
[22] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[23] Andrew D. Mathis,et al. Metabolic-Stress-Induced Rearrangement of the 14-3-3ζ Interactome Promotes Autophagy via a ULK1- and AMPK-Regulated 14-3-3ζ Interaction with Phosphorylated Atg9 , 2014, Molecular and Cellular Biology.
[24] J. Banchereau,et al. SnapShot: Cancer Vaccines , 2014, Cell.
[25] P. Coulie,et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.
[26] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[27] R. Khanna,et al. Autophagy mediates transporter associated with antigen processing-independent presentation of viral epitopes through MHC class I pathway. , 2012, Blood.
[28] R. Scolyer,et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[30] F. Di Virgilio,et al. Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.
[31] J. Wolchok,et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab , 2011, Proceedings of the National Academy of Sciences.
[32] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[33] J. Allison,et al. Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance , 2010, Proceedings of the National Academy of Sciences.
[34] Maojun Yang,et al. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. , 2010, Molecular cell.
[35] K. Tracey,et al. Endogenous HMGB1 regulates autophagy , 2010, The Journal of cell biology.
[36] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[37] J. Tschopp,et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.
[38] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[39] W. Sterry,et al. Coordinated expression of clustered cancer/testis genes encoded in a large inverted repeat DNA structure. , 2008, Gene.
[40] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[41] G. Freeman,et al. Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.
[42] I. Davis,et al. Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage , 2006, Clinical Cancer Research.
[43] Lloyd J. Old,et al. Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.
[44] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[45] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[46] Paul Theodor Pyl,et al. HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[47] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[48] Pierre van der Bruggen,et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family , 2005, Immunogenetics.
[49] G. Schuler,et al. MAGE-A3 is a frequent tumor antigen of metastasized melanoma , 2004, Archives of Dermatological Research.